Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study

Experimental and Molecular Pathology

Volumn 87, Issue 3, 2009, Pages 178-183

  Rau, Jill C ^a   Deans, Carolyn ^b   Hoffman, Maureane R ^a,c   Thomas, David B ^a   Malcom, Gray T ^d   Zieske, Arthur W ^d   Strong, Jack P ^d   Koch, Gary G ^b   Church, Frank C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c Pathology and Laboratory Medicine Service   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Heparin cofactor II; Immunohistochemistry; PDAY; Serpins; Thrombin

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ANTITHROMBIN; HEPARIN COFACTOR II; PROTHROMBIN;

ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; PROTEIN LOCALIZATION; STAINING; TISSUE DISTRIBUTION;

ADOLESCENT; ADULT; ANIMALS; ATHEROSCLEROSIS; CORONARY VESSELS; HEPARIN COFACTOR II; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NECROSIS; PROTHROMBIN; YOUNG ADULT;

MUS;

EID: 70350778462     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2009.09.003     Document Type: Article

References (30)

1. Aihara K., Azuma H., Takamori N., Kanagawa Y., Akaike M., Fujimura M., Yoshida T., Hashizume S., Kato M., Yamaguchi H., Kato S., Ikeda Y., Arase T., Kondo A., and Matsumoto T. Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation 109 (2004) 2761-2765
2. Aihara K., Azuma H., Akaike M., Ikeda Y., Sata M., Takamori N., Yagi S., Iwase T., Sumitomo Y., Kawano H., Yamada T., Fukuda T., Matsumoto T., Sekine K., Sato T., Nakamichi Y., Yamamoto Y., Yoshimura K., Watanabe T., Nakamura T., Oomizu A., Tsukada M., Hayashi H., Sudo T., Kato S., and Matsumoto T. Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice. J. Clin. Invest. 117 (2007) 1514-1526
3. Baykal D., Schmedtje J.F., and Runge M.S. Role of thrombin receptor in restenosis and atherosclerosis. Am. J. Cardiol. 75 (1995) 82B-87B
4. Burnett M.S., Lee C.W., Kinnaird T.D., Stabile E., Durrani S., Dullum M.K., Devaney J.M., Fishman C., Stamou S., Canos D., Zbinden S., Clavijo L.C., Jang G.J., Andrews J.A., Zhu J., and Epstein S.E. The potential role of resistin in atherogenesis. Atherosclerosis 182 (2005) 241-248
5. Cornhill J.F., Herderick E.E., and Vince D.G. The clinical morphology of human atherosclerotic lesions. Lessons from the PDAY Study. Pathobiological Determinants of Atherosclerosis in Youth. Wien. Klin. Wochenschr. 107 (1995) 540-543
6. Feletou M., and Vanhoutte P.M. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am. J. Physiol., Heart Circ. Physiol. 291 (2006) H985-1002
7. Harker L.A., Hanson S.R., and Runge M.S. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am. J. Cardiol. 75 (1995) 12B-17B
8. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 27-36
9. Huang P.H., Leu H.B., Chen J.W., Wu T.C., Lu T.M., Yu-An Ding P., and Lin S.J. Decreased heparin cofactor II activity is associated with impaired endothelial function determined by brachial ultrasonography and predicts cardiovascular events. Int. J. Cardiol. 114 (2007) 152-158
10. Kaikita K., Takeya M., Ogawa H., Suefuji H., Yasue H., and Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J. Pathol. 188 (1999) 180-188
11. Liu L., Dewar L., Song Y., Kulczycky M., Blajchman M.A., II J.W.F., Andrew M., Delorme M., Ginsberg J., Preissner K.T., and Ofosu F.A. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb. Haemost. 73 (1995) 405-412
12. McGill Jr. H.C., McMahan C.A., and Gidding S.S. Preventing heart disease in the 21st century; implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation 117 (2008) 1216-1227
13. O'Brien K.D., Olin K.L., Alpers C.E., Chiu W., Ferguson M., Hudkins K., Wight T.N., and Chait A. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 98 (1998) 519-527
14. Rau J.C., Beaulieu L.M., Huntington J.A., and Church F.C. Serpins in thrombosis, hemostasis and fibrinolysis. J. Thromb. Haemost. 5 Suppl. 1 (2007) 102-115
15. Schillinger M., Exner M., Sabeti S., Mlekusch W., Amighi J., Handler S., Quehenberger P., Kalifeh N., Wagner O., and Minar E. High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting. Thromb. Haemost. 92 (2004) 1108-1113
16. Shirk R.A., Church F.C., and Wagner W.D. Arterial smooth muscle cell heparan sulfate proteoglycans accelerate thrombin inhibition by heparin cofactor II. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 1138-1146
17. Shirk R.A., Parthasarathy N., San Antonio J.D., Church F.C., and Wagner W.D. Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. J. Biol. Chem. 275 (2000) 18085-18092
18. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 266-274
19. Stary H.C., Chandler A.B., Glagov S., Guyton J.R., Insull Jr. W., Rosenfeld M.E., Schaffer S.A., Schwartz C.J., Wagner W.D., and Wissler R.W. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler. Thromb. 14 (1994) 840-856
20. Stary H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull W., Rosenfeld M.E., Schwartz C.J., Wagner W.D., and Wissler R.W. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1512-1531
21. Stoop A.A., Lupu F., and Pannekoek H. Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: a potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1143-1149
22. Strong J.P., Malcom G.T., Oalmann M.C., and Wissler R.W. The PDAY Study: natural history, risk factors, and pathobiology. Pathobiological determinants of atherosclerosis in youth. Ann. N. Y. Acad. Sci. 811 (1997) 226-235 discussion 235-7
23. Strong J.P., Malcom G.T., McMahan C.A., Tracy R.E., Newman W.P., Herderick E.E., and Cornhill J.F. Prevalence and extent of atherosclerosis in adolescents and young adults. Implications for prevention from the pathobiological determinants of atherosclerosis in youth study. JAMA 281 (1999) 727-735
24. Sun H., Koike T., Ichikawa T., Hatakeyama K., Shiomi M., Zhang B., Kitajima S., Morimoto M., Watanabe T., Asada Y., Chen Y.E., and Fan J. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am. J. Pathol. 167 (2005) 1139-1148
25. Takamori N., Azuma H., Kato M., Hashizume S., Aihara K., Akaike M., Tamura K., and Matsumoto T. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation 109 (2004) 481-486
26. Tollefsen D.M. Heparin cofactor II modulates the response to vascular injury. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 454-460
27. Tovar A.M., de Mattos D.A., Stelling M.P., Sarcinelli-Luz B.S., Nazareth R.A., and Mourao P.A. Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochim. Biophys. Acta 1740 (2005) 45-53
28. Vicente C.P., He L., and Tollefsen D.M. Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Blood 110 (2007) 4261-4267
29. Wissler R.W. New insights into the pathogenesis of atherosclerosis as revealed by PDAY. Pathobiological determinants of atherosclerosis in youth. Atherosclerosis 108 Suppl. (1994) S3-20
30. Wyler von Ballmoos M., Dubler D., Mirlacher M., Cathomas G., Muser J., and Biedermann B.C. Increased apolipoprotein deposits in early atherosclerotic lesions distinguish symptomatic from asymptomatic patients. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 359-364